CAS: 15802-75-2; 4-Iodo-3-Methyl-1H-Pyrazole

相似化合物

2033-45-6 1354703-91-5 1269449-59-3

上下游产品

3-Methylpyrazole 4-iodo-3,5-dimethyl-1H-pyrazole (5)-methylpyrazole3(5)-methylpyrazole ethyl trans-4-(4-iodo-3-methyl-1H-pyrazol-1-yl)cyclohexanecarboxylate ethyl trans-4-(4-iodo-5-methyl-1H-pyrazol-1-yl)cyclohexanecarboxylate 1-[3-(benzyloxy)propyl]-4-iodo-3-methyl-1H-pyrazole 1-[3-(benzyloxy)propyl]-4-iodo-5-methyl-1H-pyrazole

3-甲基吡唑置于ammonium Cerium(Iv) Nitrate,碘体系中,用 乙腈 用作溶剂,化学反应 3.0H,以90%的收率获得3-甲基-4-碘吡唑
参考文献:一种温和有效的吡唑区域选择性碘化方法
标题:一种温和有效的吡唑区域选择性碘化方法
摘要:在can作为原位氧化剂存在下,使用元素碘对n-H或n-苄基吡唑进行碘化是一种温和而有效的方法,用于制备甚至具有吸电子取代基的4-碘吡唑.该反应是区域选择性的,因为碘原子优选吡唑而不是苄基,并且4-吡唑位置而不是杂环中其他可能的位置.
Doi:10.1016/s0040-4039(00)02136-5

专利信息

专利号:US-8445510-B2
优先权日:2010-05-14
标题 :Fused bicyclic kinase inhibitors
发明人：MULVIHILL MARK J; STEINIG ARNO G; CREW ANDREW PHILIP; JIN MEIZHONG; KLEINBERG ANDREW; LI AN-HU; WANG JING
权利人:MULVIHILL MARK J; STEINIG ARNO G; CREW ANDREW PHILIP; JIN MEIZHONG; KLEINBERG ANDREW; LI AN-HU; WANG JING; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula I, as shown below and defined herein: n n n n n n n n n n pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

专利号:CN-111205226-A
优先权日:2020-01-22
标题 :Synthesis method of 1-methyl-4-iodopyrazole

专利号:US-9133224-B2
优先权日:2010-11-29
标 题:Macrocyclic kinase inhibitors
发明人：CREW ANDREW P; DONG HANQING; FERRARO CATERINA; SHERMAN DAN; SIU KAM W
权利人:CREW ANDREW P; DONG HANQING; FERRARO CATERINA; SHERMAN DAN; SIU KAM W; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.